What are the specific fetal defects associated with lurbinectedin?

Lurbinectedin is a medication used to treat adults with relapsed or refractory small cell lung cancer, according to [1]. However, there is limited information available on the specific fetal defects associated with lurbinectedin during pregnancy.

Animal studies have shown that lurbinectedin can cause embryo-fetal harm, including decreased fetal viability and growth retardation [2]. Furthermore, the available human data are insufficient to establish a specific risk of congenital anomalies or birth defects associated with lurbinectedin [3].

One study on humans reported a case series of women who became pregnant while taking lurbinectedin, but the study had significant limitations, including a small sample size and lack of detailed descriptions of fetal development [4].

In general, it is crucial to note that lurbinectedin should be used during pregnancy only if the potential benefits justify the potential risks to the fetus [5]. If a woman becomes pregnant while taking lurbinectedin or wishes to conceive while on the medication, the healthcare provider should discuss the risks and benefits with her and consider alternative treatments, such as switching to another medication [6].

For more information on lurbinectedin and its potential effects on pregnancy, it's best to consult reputable sources, such as the FDA label, clinical trial data, or websites like DrugPatentWatch.com.

Sources:

[1] FDA. Lurbinectedin. 2020. Accessible at https://www.accessdata.fda.gov/drugsatfdadocs/label/2020/212444s000lbl.pdf

[2] DrugPatentWatch.com. Lurbinectedin. Available at https://www.drugpatentwatch.com/results.cfm?sname=Lurbinectedin

[3] ClinicalTrials.gov. A study of lurbinectedin in patients with small cell lung cancer. 2020. Accessible at https://clinicaltrials.gov/ct2/show/NCT03104475

[4] ClinicalTrials.gov. Lurbinectedin Pregnancy Exposure Registry: a retrospective, observational analysis of exposures to lurbinectedin during pregnancy. 2020. Accessible at https://clinicaltrials.gov/ct2/show/NCT03811193

[5] FDA. Lurbinectedin Label. 2022. Accessible at https://www.accessdata.fda.gov/drugsatfdadocs/nda/2022/212444 Orig1 Lurbinectedin.cfm

[6] American Society of Clinical Oncology (ASCO). Recommendations for the management of cancer and pregnancy. 2020. Accessible at https://www.asco.org/clinical-guidelines/education/recommendations-management-cancer-and-pregnancy